[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 13 days · First seen · Last updated

Immutep immunotherapy development and funding

Overview

Immutep is undergoing strategic and financial developments regarding its immunotherapy candidates, efti and IMP761. The company has refocused the development of eftilagimod alpha (efti) toward first-line head and neck cancer patients and the neoadjuvant treatment of soft tissue sarcoma. This shift follows a root cause analysis of the TACTI-004 trial, which identified structural differences in the manufactured product’s N-glycan structure. Immutep has initiated a new 200-litre manufacturing run and expects to return efti to clinical development in the second half of 2027.

In support of its research, Immutep received an A$0.86 million cash rebate from the Australian Federal Government’s R&D tax incentive program for expenditures incurred during the 2025 fiscal year. The company is also utilizing tax incentives in France and Germany through its subsidiaries. Immutep intends to use this non-dilutive funding to advance its product candidates, with an expected cash reach extending into the first half of CY2028.

Entities

Immutep Limited · Immutep · AusIndustry · FDA · Marc Voigt

Timeline

  1. [BUSINESS] 2 sources
    Immutep receives A$0.86 million Australian R&D tax incentive

    Immutep Limited has received an A$856,669 R&D tax incentive from the Australian government to support its immunotherapy research for cancer and autoimmune diseases.

  2. [BUSINESS] 2 sources
    Immutep refocuses efti development on cancer treatments

    Immutep is refocusing eftilagimod alpha (efti) development on head and neck cancer and soft tissue sarcoma, aiming to return the candidate to clinical trials by the second half of 2027.

Sources

finnewsnetwork.com.au · marketwire.com · seekingalpha.com · sharecafe.com.au